The HIV medicine market size was valued at US$28 billion in 2018 and has grown at close to 10% since 2014.
With key brand patent expiration's coming in the next 5 years market growth is expected to slow down. A lower CAGR is expected for HIV drugs until 2026 where after growth is expected to become negative.
Growing at 14% for the last 5 years the North American markets accounted for 65% of the overall HIV drug market in 2016. The North American market is expected to continue growing at a lower CAGR of 0.45% for the next 10 years but still account for close to 70% of the total global market.
 
Pharma14 global medicine index continuously tracks all HIV medicine prices and consumption with standard monthly updates.
 
Sample data:
Top selling HIV medicines. Germany snapshot. . Atripla, Isentress, Prezista, Stribild, Tivicay, Triumeq, Truvada, Viread.